Personalized Health Care (PHC) in Cancer - Genomic Biomarkers for Pharmaceutical Development - page 43

References
[1] Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug
Discov 2009;8(1):15-16.
[2] Deininger MW, Druker BJ. Speciic targeted therapy of chronic myelogenous leukemia with imatinib.
Pharmacol Rev 2003;55:401-23.
[3] Wodarz D. Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune
responses. Proc Biol Sci 2010;277:1875-80.
[4] Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: suggestions of a new method
of treatment with illustrative cases. Lancet 1896;2:162-5.
[5] De Sombre ER, Smith S, Block GE, Ferguson DJ, Jensen EV. Prediction of breast cancer response to endocrine
therapy. Cancer Chemother Rep 1974;58:513-19.
[6] Puhalla S, Bhattacharya S, Davidson N. Hormonal therapy in breast cancer: a model disease for the person-
alization of cancer care. Molec Oncol 2012;6:222-36.
[7] Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, et al. NCCN Task force report: estro-
gen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr
Canc Netw 2009;7(Suppl. 6):S1-S21.
[8] Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is supe-
rior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin
Oncol 1999;17:1474-81.
[9] McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer: an overview.
In: McGuire WL, Carbone PP, Vollner EP, editors. Estrogen receptors in human breast cancer. New York:
Raven Press; 1975. pp. 1-8.
[10] Early Breast Cancer Trialist's Collaborative Group Tamoxifen for early breast cancer: an overview of rand-
omized trials. Lancet 1998;351:1451-67.
[11] Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effect of chemotherapy and hormone ther-
apy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet
2005;365:1687-717.
[12] Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006;43:325-47.
[13] Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev
Cancer 2009;9:631-43.
[14] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of
relapse and survival with ampliication of the HER-2 / neu oncogene. Science 1987;235:177-82.
[15] Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. HER-2 signaling and inhibition in breast cancer.
Curr Cancer Drug Ther 2009;9:419-38.
[16] Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 recep-
tor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist
2009;14:320-68.
[17] Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast
cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92-8.
[18] Hudis CA. Trastuzumab, mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
[19] Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efi-
cacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing meta-
static breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
[20] Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus
a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Eng J Med
2001;344:783-92.
[21] Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of
early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist
2008;13:620-30.
[22] Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE. Trastuzumab plus adjuvant chemo-
therapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
[23] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I. Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.